NantKwest
E932805
NantKwest is a biotechnology company focused on developing natural killer (NK) cell-based immunotherapies for cancer and other diseases.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| aimsTo |
treat cancer
ⓘ
treat infectious diseases ⓘ treat inflammatory diseases ⓘ |
| basedIn |
California, United States
ⓘ
surface form:
California
|
| boardMember | Patrick Soon-Shiong NERFINISHED ⓘ |
| chiefExecutiveOfficer | Patrick Soon-Shiong NERFINISHED ⓘ |
| collaboratesWith | ImmunityBio NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
allogeneic NK cell therapies
ⓘ
off-the-shelf NK cell therapies ⓘ |
| focusesOn |
cancer immunotherapy
ⓘ
immunotherapies for infectious diseases ⓘ immunotherapies for inflammatory diseases ⓘ natural killer cell-based immunotherapies ⓘ |
| foundedBy | Patrick Soon-Shiong NERFINISHED ⓘ |
| founder | Patrick Soon-Shiong NERFINISHED ⓘ |
| hasAbbreviation | NK NERFINISHED ⓘ |
| hasApproach | allogeneic, off-the-shelf cell therapy ⓘ |
| hasBusinessModel | clinical-stage biopharmaceutical development ⓘ |
| hasKeyPerson | Patrick Soon-Shiong NERFINISHED ⓘ |
| hasPipeline | clinical-stage NK cell therapeutics ⓘ |
| hasResearchFocus |
antibody-dependent cellular cytotoxicity enhancement
ⓘ
combination immunotherapy ⓘ tumor-targeted NK cell therapy ⓘ |
| hasTechnologyPlatform |
activated natural killer cell platform
ⓘ
off-the-shelf NK cell platform ⓘ |
| headquartersLocation | San Diego, California NERFINISHED ⓘ |
| industry | biotechnology ⓘ |
| mergedInto | ImmunityBio NERFINISHED ⓘ |
| parentOrganization | ImmunityBio NERFINISHED ⓘ |
| partOf | NantWorks ecosystem NERFINISHED ⓘ |
| targetPatientGroup |
cancer patients
ⓘ
patients with infectious diseases ⓘ patients with inflammatory diseases ⓘ |
| therapeuticArea |
autoimmune diseases
ⓘ
infectious diseases ⓘ oncology ⓘ |
| tickerSymbol | NK NERFINISHED ⓘ |
| tradedOn | NASDAQ NERFINISHED ⓘ |
| usesCellType |
CD16 receptor-expressing NK cells
ⓘ
natural killer cells ⓘ |
| usesMechanismOfAction |
activation of natural killer cells
ⓘ
antibody-dependent cellular cytotoxicity ⓘ |
| usesModality |
cell therapy
ⓘ
immunotherapy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.